Tag: ATX
Amplia Therapeutics readies for phase 2 pancreatic cancer trial after lead drug manufactured
Amplia Therapeutics (ASX: ATX) is a step closer to phase 2 clinical trials in pancreatic cancer and lung fibrosis after completing a manufacturing run of its lead focal adhesion kinase (FAK) inhibitor...
Amplia Therapeutics receives $2.1m grant to fast-track second cancer drug AMP886
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has been granted a $2.1 million government funding facility to accelerate work on its second focal adhesion kinase (FAK) inhibitor drug AMP886 for...
Amplia Therapeutics confirms anti-cancer drug AMP945 can inhibit focal adhesion kinase in healthy volunteers
Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has received new data from a recent phase 1 clinical trial, which demonstrates the ability of lead drug AMP945 to inhibit focal adhesio...
Amplia Therapeutics secures renowned oncology drug development expert as clinical advisor
Amplia Therapeutics (ASX: ATX) has appointed experienced spearhead of pancreatic cancer treatments Dr José Iglesias as clinical advisor to assist with development of its cancer and fibroid drugs.
T...
Amplia Therapeutics receives $1.14m tax refund for cancer drug development expenses
Clinical development company Amplia Therapeutics (ASX: ATX) has received a research and development tax incentive refund from the federal government for expenditure related to advancing its focal adhe...
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer
New research describing the fundamental biology behind Amplia Therapeutics’ (ASX: ATX) planned phase 2 clinical trial on pancreatic cancer patients has highlighted the potential benefits of using a fo...
Amplia Therapeutics completes design of phase 2 AMP945 trial to treat advanced pancreatic cancer
Australian pharmaceutical company Amplia Therapeutics (ASX: ATX) has completed the design for a phase 2 clinical trial of its focal adhesion kinase (FAK) inhibitor AMP945 for the treatment of advanced...
Amplia Therapeutics prepares for phase two AMP945 trial backed by shareholders
Amplia Therapeutics (ASX: ATX) will be spending the September quarter finalising the design of phase two clinical trials of its lead drug AMP945 in both pancreatic cancer and idiopathic lung fibrosis ...
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has announced the unblinded results of a phase one clinical trial that supports further development of its drug AMP945 in cancer and fibrosis.
...
Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has finalised a deal with the Garvan Institute of Medical Research in Sydney to collaborate on the development of Amplia’s drug AMP945 to treat pa...
Amplia Therapeutics receives second orphan drug designation for treatment of chronic lung disease
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received a second orphan drug designation from the US Food and Drug Administration for its focal adhesion kinase inhibitor AMP945.
The desi...
Amplia Therapeutics receives FDA orphan drug designation for pancreatic cancer
Pharmaceutical company Amplia Therapeutics (ASX: ATX) has received regulatory approval from the US Food and Drug Administration (FDA) for its Focal Adhesion Kinase inhibitor (FAKi) AMP945 – a novel ne...
